BG Medicine Partners with Siemens on Automated Version of Galectin-3 Heart Failure Prognostic

According to its recently amended preliminary prospectus for its initial public offering, the company hopes to submit a 510(k) pre-market notification to the FDA for an automated test by the fourth quarter of 2011, and to have such a test on the market in the first half of 2012.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.